



Disease Severity Determines Timing of Initiating Continuous Renal Replacement Therapies: A Systematic Review and Meta-Analysis

Zi-Jing Xia^{1†}, Lin-ye He^{2†}, Shu-Yue Pan^{1,3}, Rui-Juan Cheng¹, Qiu-Ping Zhang¹ and Yi Liu^{1*}

¹ Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China, ² Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, China, ³ Department of Rheumatology and Immunology, Chengdu Fifth People's Hospital, Chengdu, China

OPEN ACCESS

Edited by:

Alexandre Liborio, University of Fortaleza, Brazil

Reviewed by:

Francesco Garzotto, Veneto Institute of Oncology (IRCCS), Italy Andrea Angeletti, Division of Nephrology and Kidney Transplantation, Giannina Gaslini Institute (IRCCS), Italy

*Correspondence:

Yi Liu yi2006liu@163.com

[†]These authors share first authorship

Specialty section:

This article was submitted to Nephrology, a section of the journal Frontiers in Medicine

Received: 04 July 2020 Accepted: 20 September 2021 Published: 18 November 2021

Citation:

Xia Z-J, He L-y, Pan S-Y, Cheng R-J, Zhang Q-P and Liu Y (2021) Disease Severity Determines Timing of Initiating Continuous Renal Replacement Therapies: A Systematic Review and Meta-Analysis. Front. Med. 8:580144. doi: 10.3389/fmed.2021.580144 **Background:** Timing of initiating continuous renal replacement therapies (CRRTs) among the patients with acute kidney injury (AKI) in intensive care units (ICU) has been discussed over decades, but the definition of early and late CRRT initiation is still unclear.

Methods : The English language randomized controlled trials (RCTs) and cohort studies were searched through MEDLINE, EMBASE, and Cochrane Library on July 19, 2019, by the two researchers independently. The study characteristics; early and late definitions; outcomes, such as all-cause, in-hospital, 28- or 30-, 60-, 90-day mortality; and renal recovery were extracted from the 18 eligible studies. Pooled relative risk ratios (RRs) and 95% Cls were estimated with the fixed effects model and random effects model as appropriate. This study is registered with PROSPERO (CRD 42020158653).

Results: Eighteen studies including 3,914 patients showed benefit in earlier CRRT (n = 1,882) over later CRRT (n = 2,032) in all-cause mortality (RR 0.78, 95% CI 0.66–0.92), in-hospital mortality (RR 0.81, 95% CI 0.67–0.99), and 28- or 30-day mortality (RR 0.81, 95% CI 0.74–0.88), but in 60- and 90-day mortalities, no significant benefit was observed. The subgroup analysis showed significant benefit in the disease-severity-based subgroups on early CRRT initiation in terms of in-hospital mortality and 28- or 30-day mortality rather than the time-based subgroups. Moreover, early CRRT was found to have beneficial effects on renal recovery after CRRT (RR 1.21, 95% CI 1.01–1.45).

Conclusions: Overall, compared with late CRRT, early CRRT is beneficial for short-term survival and renal recovery, especially when the timing was defined based on the disease severity. CRRT initiation on Acute Kidney Injury Network (AKIN) stage 1 or Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE)-Risk or less may lead to a better prognosis.

Keywords: continuous renal replacement therapies, CRRT, timing, acute kidney injury, AKI

1

INTRODUCTION

Acute kidney injury (AKI) is one of the most common complications in the intensive care unit (ICU) with a 10-30% rate of hospitalization (1–3). Along with a 2–5 times risk of mortality (4)of non-AKI patients, AKI has been considered the most dangerous killer in the ICU.

Renal replacement therapy (RRT), along with other general and medical therapy, is now the primary management strategy of patients with AKI. With basic modes, such as continuous renal replacement therapy (CRRT) and intermittent renal hemodialysis (IHD), this strategy can replace and support renal function during the AKI course. With appropriate initiation timing, CRRT can theoretically be more suitable for maintaining the hemodynamic stability of patients and removing certain small molecular toxins, which can significantly improve the prognosis and reduce the mortality of the patients with AKI (5–7).

At present, despite the improvement in CRRT technology, the timing of CRRT initiation is still under intense discussion and the evidence guiding clinicians in initiating CRRT in critical diseases is still limited. One of the most important barriers is that the studies on early and late CRRT are not consistent; that is, different early and late definitions that reflect the diversity of time factors, biochemical indicators, and clinical parameters, were all used to balance the risk of initiating CRRT and the benefits of supporting renal function during critical illness. This can be a major cause of discrepancy in conclusions drawn by different studies, for example, "early" in one research can be recognized as "late" in another.

Earlier initiation of CRRT might provide better control of acid-base and electrolyte balance. Moreover, it can be more helpful in maintaining hemodynamic stability, reducing risks of other potential complications of AKI (8). While early initiation of CRRT can also increase the unnecessary financial burden of patients with AKI, it can increase the risk of coagulationanticoagulant disorder and even delay the recovery of renal function, which may negatively affect the prognosis of patients (9). On the contrary, late initiation of CRRT may provide more time to the patients with AKI for hemodynamic optimization before CRRT or even avoid the need for CRRT and its associated complications (10). Some systematic reviews and meta-analyses have addressed these issues and provided a hint that the patients with AKI accepting early CRRT appear to benefit from it (11, 12). However, these studies still used a mixture of early and late when defining the timing of CRRT initiation. No clear rule was used in these studies to measure the timing of CRRT initiation.

This systematic review was conducted to assess the effectiveness of the different initiation timing of CRRT among the patients with AKI in the ICU and try to address the use of inconsistent definitions of early and late in different studies by subgroup analysis.

METHODS

Overall

This systematic review with individual patient data metaanalysis was registered on PROSPERO (CRD 42020158653) and followed a prespecified analysis plan (https://www.crd. york.ac.uk/PROSPERO/). This study is reported in accordance with the Preferred Reporting Items for a Review and Metaanalysis of Individual Participant Data. The PICO principle of this study can be summarized as: Patient: patients with AKI requiring hemodialysis in ICU; Intervention: early CRRT initiation; Comparison: delayed CRRT initiation; Outcome: morality decrease.

Search Strategy

In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted this systematic review and meta-analysis to find out the effect of early and late initiation of CRRT on the outcomes of the patients with AKI requiring dialysis (13). PubMed, MEDLINE, and EMBASE databases were searched for articles comparing early and late initiation of CRRT published up to July 2019, using the search expression of (Acute kidney failure OR Acute kidney tubule necrosis OR acute kidney OR acute renal) AND (Continuous Renal replacement therapy OR dialysis OR dialyzed OR dialyzing OR hemodialysis OR hemofiltration) AND (Time to treatment OR Time OR Early intervention OR Early OR Earlier OR Timing OR Accelerated OR Accelerating OR Acceleration OR Late) AND (Critical Care OR Intensive Care Unit OR ICU).

Inclusion Criteria

The articles were included if they meet the following inclusion criteria:

- (1) Compare "early" and "late" initiation of CRRT directly on the patients with AKI aged >14 years.
- (2) Provided a clear definition of "early" and "late" initiation and outcome measurements.
- (3) Provided effective data on necessary basic characteristics and outcomes.

Exclusion Criteria

The articles were excluded if they met any of these exclusion criteria:

- (1) Studies did not focus on the patients with AKI requiring hemodialysis.
- (2) Studies that included patients aged <14 years.
- (3) Studies that included patients with chronic kidney disease or end-stage renal disease.
- (4) Studies with unoriginal data.

Only randomized and cohort studies were included. Both abstracts and full papers were used for data syntheses and quality assessment. The authors of abstracts were contacted for details if possible. Two researchers independently conducted the study searching and screening and cross-checked them after completion. If there were any differences, they would be settled through discussion or by a third investigator.

Data Extraction

For each article, data of basic characteristics, such as leading author, publication year, study design, study period, total number



of patients, mean age, sex, and biochemical laboratory tests at the initiation of CRRT; main characteristics, such as type of patient setting, definition of early and late initiation of CRRT; and main study outcomes were extracted separately by the two reviewers.

The main outcomes were as follows:

- (1) All-cause mortality (without time limitation).
- (2) In-hospital, 28- or 30-, 60-day, and 90-day mortality.
- (3) Rate of renal recovery after treatment.

Quality Assessment

The quality of randomized controlled trials (RCTs) was evaluated with Cochrane review tools recommended by the Cochrane Handbook (14) and the Newcastle–Ottawa Scale for the observational studies (15).

Subgroup Analysis

The subgroup analyses of the varying definitions of early and late initiations of CRRT from each study were conducted for the analyses of in-hospital mortality and 28- or 30-day mortality.

- 1. Studies were divided into the following subgroups based on the natural definition of early and late initiation:
 - (1). Time-based studies: these studies defined early and late initiations as the time period from ICU admission,

undertaking surgical or diagnosis with AKI (defined as T_0), to the initiation of CRRT.

- (2). Disease severity-based studies: these studies defined early and late initiations based on the disease severity factors [such as biochemical indicator levels, urine output before dialysis, Acute Kidney Injury Network (AKIN) stages, Risk, Injury, Failure, Loss of kidney function, and Endstage kidney disease (RIFLE) classification, or Sequential Organ Failure Assessment scores].
- 2. The subgroups were re-grouped based on an introduced rule:
 - (1) Based on AKIN stage of the patient or RIFLE classification: using AKIN stages and RIFLE classification provided in the included studies, the patients were re-grouped into early (defined as AKIN 1 stage or RIFLE-Risk or less) and late (defined as AKIN stages 2–3 or RIFLE-Injury or Failure) groups. The studies that did not directly provide AKIN stages or RIFLE classification but can be judged based on their definition of early and late initiation were also included.
 - (2) Based on the enrollment time period of the patient from T_0 to initiation of CRRT: the objects were regrouped into early (defined as CRRT initiation $\leq 48 \text{ h}$

References	Country	Study design	Study period	Cause of AKI	N	Male (%)	Mean age	Study qualit
Bouman et al. (17)	Netherlands	RCT	1998–2000	All cause	71	42 (59.2)	69	High
Sugahara and Suzuki (18)	America	RCT	1995–1997	Cardiac surgery (CABG)	28	18 (64.3)	64	Low
Jun et al. (19)	Australia	RCT	NA	All cause	439	282 (64.2)	64	High
Combes et al. (20)	America	RCT	2009-2012	Cardiac surgery	224	177 (79.0)	59	High
Zarkbock et al. (21)	Germany	RCT	2013-2015	All cause	231	146 (63.2)	67	High
Demirkiliç et al. (22)	Turkey	PC	1992-2001	Cardiac surgery	61	48 (78.7)	NA	9
Oh et al. (23)	Korea	PC	2009-2011	Septic	210	126 (60.0)	62	9
Campos et al. (24)	Germany	PC	2006-2011	Cardiac surgery	30	NA	65	7
Oh et al. (25)	Korea	PC	2008-2013	Septic	60	52 (86.7)	66	8
Park et al. (26)	Korea	PC	2009-2013	All cause	607	365 (60.1)	74	7
Gettings et al. (27)	America	RC	1989–1997	Trauma	100	79 (79.0)	45	9
Elahi et al. (28)	United kingdom	RC	2002-2003	Cardiac surgery	64	48 (75.0)	70	9
lyem et al. (29)	Turkey	RC	2004–2007	Cardiac surgery (CABG)	185	68 (36.8)	63	9
Shiao et al. (30)	Taiwan	RC	2002-2005	Surgery	98	57 (58.2)	66	8
Shum et al. (31)	China	RC	2008-2011	Septic	120	77 (64.2)	73	8
Wu et al. (32)	China	RC	2008-2010	Surgery	73	48 (65.8)	61	8
Tian et al. (33)	China	RC	2009-2011	Septic	100	69 (69.0)	51	8
Christiansen et al. (34)	Denmark	RC	2005-2015	All cause	1,213	838 (69.1)	68	7

AKI, acute kidney injure; CABG, coronary artery bypass graft; NA, not available; RCT, randomized controlled trial.

from T_0) and late (defined as CRRT initiation >48 h from T_0) groups.

Statistical Analyses

We assessed heterogeneity using I^2 and τ^2 statistics [I^2 values ranged from 0 to 100%, with 0% as no observed heterogeneity, 0-74% acceptable heterogeneity, \geq 75% as high heterogeneity (14)]. No meta-regression was conducted because of the small number of studies enrolled. A random effects model was used in the metaanalysis of studies with high heterogeneity ($I^2 \ge 50\%$), and a fixed effects model was chosen when the heterogeneity was low $(I^2 < 50\%)$. A Mantel-Haenszel method was used to calculate the overall risk ratios (RRs) and 95% CIs). A value of $p \le 0.05$ was considered statistically significant. Moreover, we conducted sensitivity analyses to assess the influence of clinical factors and measures of study quality on heterogeneity in the selected studies. By removing one study at a time from the analysis, the influence of each study on the conclusion was estimated, and the degree to which the pooled effect size changed was determined. A study was considered influential if its exclusion had an effect estimate of at least 20% or changed the conclusion. Publication bias and other reporting biases were then assessed with a funnel plot, by plotting the SE against the log RR, using the Egger test (16). No significant publication bias occurred when the shape of the funnel plot was symmetrical. All our analyses were performed with Review Manager version 5.2 (RevMan; Copenhagen: The Nordic Cochrane Center, the Cochrane Collaboration, 2014, London, UK) software.

RESULTS

Study Characteristics

As shown in **Figure 1**, we screened 2,019 unique articles, of which 67 were considered for full-text reviews. A total of 18 articles

(14–31) that included five RCTs (17–21), five prospective cohort studies (22–26), and eight retrospective cohort studies (27–34), were eligible for the final meta-analysis (**Table 1**). The studies were conducted from 1989 to 2017 and analyzed a total of 3,914 patients with AKI requiring CRRT. **Table 2** shows the definition of early and late CRRT initiation and the event counts of major endpoints in each study. The study conducted by Bouman et al. (17) included three cohorts, namely, early high-volume hemofiltration, early low-volume hemofiltration, and late low-volume hemofiltration, and to ensure comparability, the early high-volume hemofiltration cohort was excluded.

The included RCTs were divided into low and high quality using a cutoff with three of six domains of bias in the quality assessment tool, and only the study conducted by Sugahara and Suzuki (18) (**Figure 2**) had low quality. All non-RCTs included were considered to have high methodological quality with a recommended cutoff score of 5 (35) (**Table 1**). **Figure 3** shows the evaluated conclusion of publication bias. It can be speculated that no significant publication bias exists because the shape of the funnel plot was symmetrical. However, the publication bias was still of concern because only a small number of studies met our inclusion criteria.

Effects of Early vs. Late CRRT Initiation on Mortality

The overall pooled mortalities of enrolled studies were 43.3% (815 of 1,882) and 50.3% (1,023 of 2,032) in the early and late groups, respectively. A significant benefit was found in the early group (RR 0.78, 95% CI 0.66–0.92, p = 0.003, **Figure 4**).

Of the 18 studies, 10 reported data on in-hospital mortality, that is, 38.1% (281 of 738) in the early group and 57.3% (471 of 822) in the late group, and the benefit of early initiation was significant (RR 0.81, 95% CI 0.67–0.99, p = 0.04). In addition, 11 of 18 studies provided data on 28- or 30-day mortality, with

TABLE 2 | Definition of early and late continuous renal replacement therapy (CRRT) initiation and event counts of major endpoints in each study.

References	Definitions of	early and late	Endpoint	Counts	
	Early	Late			
Bouman et al. (17)	within 12 h if urine output <30 ml/h	Urea >40 mmol/L or K > 6.5 mmol/L	In-Hospital mortality	l:18/35 C:14/36	
			28-or 30-day mortality	I:11/35 C:9/36	
			60-day mortality	l:16/35 C:13/36	
			90-day mortality	l:16/35 C:13/36	
Sugahara and Suzuki (18)	Urine output <30 mL/h	Urine output <20 ml/h	14-day mortality	I:2/14 C:14/2	
Jun et al. (19)	Within 46 h from randomization	Over 46 h from randomization	28- or 30-day mortality	I:82/219 C:84/220	
			90-day mortality	I:91/219 C:102/220	
Combes et al. (20)	SAPS II ≤ 45	SAPS II > 45	In-hospital mortality	I:50/112 C:44/112	
			28- or 30-day mortality	I:40/112 C:40/112	
			60-day mortality	I:48/112 C:42/112	
			90-day mortality	l:51/112 C:43/112	
			Renal recovery after CRRT	I:60/112 C:66/112	
Zarkbock et al. (21)	Within 8 h from diagnosis with AKIN2 stage AKI	Within 12h from diagnosis with AKIN stage 3 AKI	28- or 30-day mortality	I:34/112 C:48/119	
			60-day mortality	I:43/112 C:60/119	
			90-day mortality	l:44/112 C:65/119	
			Renal recovery after CRRT	I:60/112 C:46/119	
Demirkiliçet al. (22)	SCr > 400 μ mol/L, K > 5.5 mmol/L	Oliguria	In-hospital mortality	I:6/27 C:29/34	
Oh et al. (23)	Within 48 h from start time of vasopressor infusion	Over 48 h from start time of vasopressor infusion	28- or 30-day mortality	I:67/105 C:92/105	
Cardenas et al. (24)	Within 48 h from cardiac surgery	Over 48 h from cardiac surgery	In-hospital mortality	I:9/15 C:10/15	
Oh et al. (25)	Within 26.4 h from the start of EGDT and CRRT	Over 26.4h from the start of EGDT and CRRT	28- or 30-day mortality	I:9/30 C:17/30	
Park et al. (26)	Median 6 h urine output \geq 0.24 mL/kg/h	Median 6 h urine output < 0.24 mL/kg/h	In-hospital mortality	l:121/303 C:182/304	
			28- or 30-day mortality	I:163/303 C:204/304	
			60-day mortality	I:170/303 C:218/304	
			90-day mortality	I:176/303 C:224/304	
Gettings et al. (27)	Urea <21.4 mmol/L	Urea >21.4 mmol/L	In-hospital mortality	I:25/41 C:47/59	
			Renal recovery after CRRT	I:16/16 C:11/12	
Elahi et al. (28)	Urine output <100 ml in 8 h	SCr > 250 mmol/L, K > 6 mmol/L	In-hospital mortality	I:8/28 C:12/36	
lyem et al. (29)	RRT on admission	After 48 h when anuric	In-hospital mortality	I:5/95 C:6/90	
Shiao et al. (30)	RIFLE criteria (risk)	RIFLE criteria (injury and failure)	In-hospital mortality	l:22/51 C:35/47	
			28- or 30-day mortality	I:14/51 C:19/47	
			60-day mortality	I:23/51 C:32/47	
			90-day mortality	I:29/51 C:38/47	
			Renal recovery after CRRT	I:22/51 C:10/47	
Shum et al. (31)	RIFLE criteria (risk)	RIFLE criteria (injury and failure)	In-Hospital mortality	l:17/31 C:48/89	
			28- or 30-day mortality	l:15/31 C:43/89	
			90-day mortality	I:19/31 C:49/89	
			Renal recovery after CRRT	I:15/16 C:44/46	

(Continued)

TABLE 2 | Continued

References	Definitions	s of early and late	Endpoint	Counts
	Early	Late		
Wu et al. (32)	RIFLE criteria (risk)	RIFLE criteria (injury and failure)	28- or 30-day mortality	I:8/20 C:41/53
			90-day mortality	I:10/20 C:45/53
Tian et al. (33)	AKIN stage 1	AKIN stage ≥2	28- or 30-day mortality	I:6/23 C:43/77
			Renal recovery after CRRT	I:18/23 C:26/77
Christiansen et al. (34)	AKIN stage 2 or less	AKIN stage 3	90-day mortality	I:326/621 C:269/592

I, intervention group; *C*, control group; *AKIN criteria* (stage 1), serum creatinine by 1.5–1.9 times the baseline or \geq 0.3 mg/dl (\geq 26.5 µmol/L) increase or urine output <0.5 mL/kg/h × 6–12 h; stage 2, increase in serum creatinine by 2.0–2.9 times the baseline or urine output <0.5 mL/kg/h over 12 h; stage 3, serum creatinine by 3 times the baseline or \geq 4.6 mg/dl (\geq 353.6 µmol/L) increase or initiation of RRT or in patients aged <18 years a decrease in eGFR < 35 ml/min/1.73 m². RIFLE criteria (Risk), increase in serum creatinine by 1.5 times or urine output <0.5 ml/kg/h × 12 h; failure, increase in serum creatinine by 3 times or urine output <0.3 ml/kg/h × 24 h. AKIN, Acute Kidney Injury Network; CRRT, continuous renal replacement therapy; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; EGDT, early goal-directed therapy.

43.1% (449 of 1,041) in the early group and 53.7% (640 of 1,504) in the late group reaching this event. Similar benefit was found in the early group (RR 0.81, 95% CI 0.74–0.88, p < 0.001).

However, no specific positive effect was found in 60- and 90day mortality. We believed that substantial heterogeneity existed among these studies in most of the analyses, except for analysis on 28- or 30-day mortality ($I^2 = 32\%$, p = 0.1, **Figure 5**).

Effects of Early vs. Late CRRT Initiation on Renal Recovery

Of the 18 studies, seven reported data on renal recovery after CRRT. For this event, 316 of 471 patients (67.1%) in the early group and 332 of 575 patients (57.7%) in the late group reached a renal recovery after CRRT. The pooled analysis demonstrated a significant difference in this outcome between the two groups (RR 1.21, 95% CI 1.01–1.45, p = 0.03), while the heterogeneity was still significant ($I^2 = 80\%$, p < 0.001, **Figure 6**).

Subgroup Analysis

To investigate factors of heterogeneity, the subgroup analyses based on the early and late definitions were conducted.

The researchers of five studies used the time-based separations to define the early and late cohorts (19, 23–25, 29), others used disease severity-related standards for their definition (18, 20, 22, 26–28, 30–34), while Bouman et al. (17) and Zarkbock et al. (21) used a time-and-disease-severity combined definition to separate the early and late cohorts.

The significant differences in the effects of timings of CRRT initiation on in-hospital mortality were found in the disease severity-based study subgroups (RR 0.73, 95% CI 0.58–0.93, p = 0.01) and the disease severity re-grouped subgroups (RR 0.69, 95% CI 0.55–0.88, p = 0.003), but no difference was found either in the time-based subgroup or time-based re-grouped subgroup. The subgroup difference analysis indicated that the heterogeneity might not exist between the subgroups ($l^2 = 0\%$, p = 0.8, **Figure 7**).

In the subgroup analysis of 28- or 30-day mortality, a similar significant benefit was found in the early initiation of CRRT in the disease severity-based study subgroup (RR 0.79, 95%)

CI 0.65–0.96, p = 0.01) and the re-grouped analysis based on the disease severity subgroup (RR 0.81, 95% CI 0.72–0.92, p < 0.001). However, no difference was still found in the time-based study subgroup or the time-based re-grouped subgroup. The heterogeneity analysis showed the same negative outcome in this subgroup analysis ($I^2 = 0\%$, p = 0.9, **Figure 8**)

Sensitivity and Influence Analysis

The influence of each study was examined by removing one study at a time from the analysis. Any study excluded from the analysis should not change the conclusion or reach a 20% change of the result in the analysis of main outcomes.

DISCUSSION

This study focused on the initiation timing of CRRT, which is considered as a primary management of patients with AKI in the ICU. The results of 18 studies with 3,914 patients were combined in our meta-analysis, and we found that the early initiation of CRRT could improve the status of the patients with AKI in terms of in-hospital and 28- or 30-day mortality and could be beneficial for renal recovery after CRRT. Furthermore, the subgroup analysis shows a significant benefit of earlier stage of AKI CRRT initiation. To our best knowledge, our study was a very first one to perform this subgroup analysis and put forward the viewpoint that disease severity (AKI stages) should be considered first when evaluating the timing of CRRT initiation.

Timing of CRRT initiation has been discussed over the decades. The actual initiation timing of CRRT in clinical work varies a lot, as it is greatly affected by the subjective judgment of physicians and the distribution of medical resources (36). However, there is still no consensus on whether earlier CRRT initiation can benefit the patients with AKI.

Recently, several large RCTs focused on the CRRT initiation timing (21, 37, 38), which had intensified the discussion of this topic. Our result was consistent with the work of Zarkbock et al. (21), who included 231 patients. They defined early strategy as an initiation of CRRT within 8 h from the diagnosis of AKIN stage 2 and late strategy as initiation within 12 h from diagnosis



of AKIN stage 3 and found that early initiation had beneficial effects in 28-, 60-, and 90-day mortalities and RRT dependence after therapy. However, Gaudry et al. (37) and Barbar et al. (38) presented opposite views. Gaudry et al. (37) enrolled 620 patients and randomized them into early and late initiations. The early strategy was indicated as an RRT implementation at the time of randomization and the late strategy was taken under absolute dialysis indicators (in the patients without the indicators shown during ICU stay, RRT was not initiated). The 60-day mortality was measured as the primary outcome in this

study, and the authors found no difference in these strategies, but the lowest and highest mortality rates were found in the non-RRT group and RRT group with late initiation, respectively, which coincided with our conclusion. Meanwhile, Barbar et al. (38) enrolled 488 patients and randomized them into early and late strategies with a cutoff time period after randomization for 12 h. The patients were followed for 90 days after RRT, and mortality was measured as a primary outcome; similarly, no benefit was found in the early group. Unfortunately, none of these two studies had given prerequisite data describing the CRRT



	Early init		late initi			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total		M-H, Random, 95% Cl	M-H, Random, 95% Cl
Barbar 2018	138	239	128	238	0.0%	1.07 [0.91, 1.26]	
Bouman 2002	18	35	14	36	4.9%	1.32 [0.79, 2.23]	
Cardenas 2015	9	15	10	15	4.6%	0.90 [0.52, 1.55]	
Christiansen 2017	326	621	269	592	9.2%	1.16 [1.03, 1.30]	-
Combes 2015	50	112	44	112	7.2%	1.14 [0.83, 1.55]	
Demirkilic 2004	6	27	19	34	3.1%	0.40 [0.18, 0.86]	
Elahi 2004	8	28	12	36	3.2%	0.86 [0.41, 1.81]	
Gaudry 2018	150	311	153	308	0.0%	0.97 [0.83, 1.14]	
Gettings 1999	25	41	47	59	7.6%	0.77 [0.58, 1.01]	-
lyem 2009	5	95	6	90	1.7%	0.79 [0.25, 2.50]	
Jun 2014	82	219	84	220	8.0%	0.98 [0.77, 1.25]	+
Oh 2012	67	105	92	105	8.9%	0.73 [0.62, 0.86]	-
Oh 2016	9	30	17	30	4.0%	0.53 [0.28, 0.99]	
Park 2016	121	303	182	304	8.8%	0.67 [0.57, 0.79]	-
Shiao 2009	22	51	35	47	6.6%	0.58 [0.41, 0.83]	-
Shum 2012	17	31	48	89	6.4%	1.02 [0.70, 1.48]	+
Sugahara 2004	2	14	12	14	1.3%	0.17 [0.05, 0.61]	<u> </u>
Tian 2014	6	23	43	77	3.4%	0.47 [0.23, 0.96]	
Wu 2012	8	20	41	53	4.5%	0.52 [0.30, 0.90]	
Zarkbock 2016	34	112	48	119	6.6%	0.75 [0.53, 1.07]	
Total (95% Cl)		1882		2032	100.0%	0.78 [0.66, 0.92]	•
Total events	815		1023				
Heterogeneity: Tau ² = (0.07; Chi² =	· 69.95, d	df = 17 (P	< 0.000	01); l² = 76	5%	0.01 0.1 1 10 100
Test for overall effect: 2	Z = 3.01 (P	= 0.003)					0.01 0.1 1 10 100 Early initiation late initiation

FIGURE 4 | Forest plot for all-cause mortality of all studies.

Study or Subgroup	Events	iation Total	Late initi Events		Weight	Risk Ratio M-H, Random, 95% C		Ratio lom, 95% Cl
Bouman 2002	18	35	14	36	8.7%	1.32 [0.79, 2.23]	-	-
Cardenas 2015	9	15	10	15	8.2%	0.90 [0.52, 1.55]		<u> </u>
							-	-
						and the second sec		
-							-	
lyem 2009	5	95	6	90	2.8%	0.79 [0.25, 2.50]		
Park 2016	121	303	182	304	16.4%	0.67 [0.57, 0.79]	-	
Shiao 2009	22	51	35	47	12.0%	0.58 [0.41, 0.83]	-	
							_	-
Sugahara 2004	2	14	12	14	2.3%	0.17 [0.05, 0.61]		
Total (95% CI)		752		836	100.0%	0 79 [0 64 0 97]	•	
	202	102	420	000	100.070	0.70 [0.04, 0.07]	•	
		00.04		0.000	12 000/			
			If = 10 (P =	= 0.003)	; 1² = 62%		0.01 0.1	1 10 100
Test for overall effect:	Z = 2.24 (P	= 0.03)					Early initiation	Late initiation
	Early init	tiation	Late ini	tiation		Risk Ratio	Risk	Ratio
Study or Subgroup	Events		Events	Tota	<u>Weight</u>	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% Cl
							-	-
							_	
						as an		_
							T	
Jun 2014	82	219	84	220) 12.4%	0.98 [0.77, 1.25]	1	
Oh 2012	67	105	92	105	13.6%	0.73 [0.62, 0.86]	-	
Oh 2016	9	30	17	30	2.5%			
						the second line second in the second		-
							_	_
						the second se		
Wu 2012								
Zarkbock 2016	34	112	48	119	6.9%	0.75 [0.53, 1.07]	-	
Total (95% CI)		1280		1430	100.0%	0.85 [0.78, 0.92]	•	
Total events	560		742					
		11 (P =)		52%			I I I	
•				/0				10 100
. Socior overall enect.	-	- 0.000	•)				Early initiation	Late initiation
	Farly init	iation	Late init	iation		Risk Patio	Piek	Ratio
Study or Subgroup	Early init		Late init		Weight	Risk Ratio M-H Random 95% C		Ratio
Study or Subgroup	Events	Total	Events	Total	-	M-H, Random, 95% C	M-H, Rand	Ratio dom, 95% Cl
Bouman 2002	Events 16	Total 35	Events 13	Total 36	6.4%	M-H, Random, 95% C 1.27 [0.72, 2.23]	I M-H, Rang	
Bouman 2002 Combes 2015	Events 16 48	Total 35 112	Events 13 42	<u>Total</u> 36 112	6.4% 14.0%	M-H. Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58]	I M-H, Rand - -	
Bouman 2002 Combes 2015 Gaudry 2018	Events 16 48 150	Total 35 112 311	Events 13 42 153	Total 36 112 308	6.4% 14.0% 24.5%	M-H, Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14]	il M-H, Rand - -	
Bouman 2002 Combes 2015	Events 16 48	Total 35 112	Events 13 42	<u>Total</u> 36 112	6.4% 14.0%	M-H. Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58]	il M-H, Rand - -	
Bouman 2002 Combes 2015 Gaudry 2018	Events 16 48 150	Total 35 112 311	Events 13 42 153	Total 36 112 308	6.4% 14.0% 24.5%	M-H, Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14]	:I M-H, Ranc - - -	
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016	Events 16 48 150 170	Total 35 112 311 303	Events 13 42 153 218	Total 36 112 308 304	6.4% 14.0% 24.5% 27.4%	<u>M-H. Random, 95% C</u> 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88]	:I M-H, Rand - - - - -	
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009	Events 16 48 150 170 23	Total 35 112 311 303 51	Events 13 42 153 218 32	Total 36 112 308 304 47 119	6.4% 14.0% 24.5% 27.4% 12.2%	<u>M-H, Random, 95% C</u> 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95]	:I M-H, Rand - - - - -	
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016	Events 16 48 150 170 23	Total 35 112 311 303 51 112	Events 13 42 153 218 32	Total 36 112 308 304 47 119	6.4% 14.0% 24.5% 27.4% 12.2% 15.4%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02]	:I M-H, Rand - - - - -	
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI)	Events 16 48 150 170 23 43 43	Total 35 112 311 303 51 112 924	Events 13 42 153 218 32 60 518	Total 36 112 308 304 47 119 926	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02]	:I M-H. Ranc 	iom. 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events	Events 16 48 150 170 23 43 43 450 0.02; Chi ² =	Total 35 112 311 303 51 112 924 = 12.13, (Events 13 42 153 218 32 60 518	Total 36 112 308 304 47 119 926	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02]	M-H. Ranc 	
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² =	Events 16 48 150 170 23 43 450 0.02; Chi ² = Z = 1.64 (P	Total 35 112 311 303 51 112 924 = 12.13, (= 0.10)	Events 13 42 153 218 32 60 518 df = 5 (P =	Total 36 112 308 304 47 119 926 0.03); F	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.83] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03]	M-H, Rand 	tom, 95% CI
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	Events 16 48 150 170 23 43 450 0.02; Chi ² = Z = 1.64 (P Early init	Total 35 112 311 303 51 112 924 = 12.13, (= 0.10) iation	Events 13 42 153 218 32 60 518 df = 5 (P = Late initia	Total 36 112 308 304 47 119 926 0.03); F ation	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] Risk Ratio	H. H. Rand H. H. Rand H. H. H	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup	Events 16 48 150 170 23 43 450 0.02; Chi ² = Z = 1.64 (P Early initi Events	Total 35 112 311 303 51 112 924 = 12.13, (= 0.10) iation Total	Events 13 42 153 218 32 60 518 df = 5 (P = Late initii Late initii Events	Total 36 112 308 304 47 119 926 0.03); F ation Total	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% <u>Weight</u>	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] Risk Ratio M-H. Random. 95% C	H. H. Rand H. H. Rand H. H. H	tom, 95% CI
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: <u>Study or Subgroup</u> Barbar 2018	Events 16 48 150 170 23 43 0.02; Chi ² = Z = 1.64 (P Early initi Events 138	Total 35 112 303 51 112 924 = 12.13, or = 0.10) iation Total 239	Events 13 42 153 218 32 60 518 df = 5 (P = Late initi Events 128	Total 36 112 308 304 47 119 926 0.03); F ation Total 238	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% 2 = 59% Weight 12.8%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] Risk Ratio M-H. Random. 95% C 1.07 [0.91, 1.26]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: <u>Study or Subgroup</u> Barbar 2018 Bouman 2002	Events 16 48 150 170 23 43 450 0.02; Chi ² = Z = 1.64 (P Early initi Events 138 16	Total 35 112 311 303 51 112 924 = 12.13, i = 0.10) iation Total 239 35	Events 13 42 153 218 32 60 518 df = 5 (P = Late initit Events 128 13	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% 2 = 59% Weight 12.8% 4.7%	M-H, Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] Risk Ratio M-H, Random, 95% C 1.07 [0.91, 1.26] 1.27 [0.72, 2.23]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: <u>Study or Subgroup</u> Barbar 2018	Events 16 48 150 170 23 43 0.02; Chi ² = Z = 1.64 (P Early initi Events 138	Total 35 112 303 51 112 924 = 12.13, or = 0.10) iation Total 239	Events 13 42 153 218 32 60 518 df = 5 (P = Late initi Events 128	Total 36 112 308 304 47 119 926 0.03); F ation Total 238	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% 2 = 59% Weight 12.8%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] Risk Ratio M-H. Random. 95% C 1.07 [0.91, 1.26]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: <u>Study or Subgroup</u> Barbar 2018 Bouman 2002	Events 16 48 150 170 23 43 450 0.02; Chi ² = Z = 1.64 (P Early initi Events 138 16	Total 35 112 311 303 51 112 924 = 12.13, i = 0.10) iation Total 239 35	Events 13 42 153 218 32 60 518 df = 5 (P = Late initit Events 128 13	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% 2 = 59% Weight 12.8% 4.7%	M-H, Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] Risk Ratio M-H, Random, 95% C 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: <u>Study or Subgroup</u> Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015	Events 16 48 150 170 23 43 450 0.02; Chi ² = Z = 1.64 (P Early initi Events 138 16 326 51	Total 35 112 311 303 51 112 924 = 12.13, (= 0.10) iation Total 239 35 621 112	Events 13 42 153 218 32 60 518 df = 5 (P = Late inititi Events 128 32 60	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36 592 112	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% <u>Weight</u> 12.8% 4.7% 13.8% 9.1%	<u>M-H. Random. 95% C</u> 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] Risk Ratio <u>M-H. Random. 95% C</u> 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014	Events 16 48 150 170 23 43 0.02; Chi² = Z = 1.64 (P Early initi Events 138 16 326 51 91	Total 35 112 311 303 51 112 924 = 12.13, (= 0.10) iation Total 239 35 621 112 219	Events 13 42 153 218 32 60 518 df = 5 (P = Late initi Events 128 13 269 43 102	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36 592 112 220	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% <u>Weight</u> 12.8% 4.7% 13.8% 9.1% 11.5%	<u>M-H. Random. 95% C</u> 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] M-H. Random. 95% C 1.07 [0.91, 1.26] 1.27 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016	Events 16 48 150 170 23 43 0.02; Chi² = Z = 1.64 (P Early initi Events 138 16 326 51 91 176	Total 35 112 311 303 51 112 924 = 12.13, (= 0.10) iation Total 239 35 621 112 219 303	Events 13 42 153 218 32 60 518 df = 5 (P = Late initi Events 128 13 269 43 102 224	Total 36 112 308 304 477 119 926 0.03); F ation Total 238 36 592 112 220 304	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% ² = 59% ² = 59% 12.8% 4.7% 13.8% 9.1% 11.5% 13.7%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] Risk Ratio M-H. Random. 95% C 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016 Shiao 2009	Events 16 48 150 170 23 43 0.02; Chi² = Z = 1.64 (P Events 138 16 326 51 91 176 29	Total 35 112 311 303 51 112 924 = 12.13, + = 0.10) iation Total 239 35 621 112 219 303 51 51 52 52 52 52 52 52 52 52 52 52	Events 13 42 153 218 32 60 518 df = 5 (P = Late initit Events 128 13 269 43 224 38	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36 592 112 220 304 47	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% 2 = 59% Weight 12.8% 4.7% 13.8% 9.1% 13.7% 9.9%	M-H, Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] M-H, Random, 95% C 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89] 0.70 [0.53, 0.93]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: <u>Study or Subgroup</u> Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016 Shiao 2009 Shum 2012	Events 16 48 150 170 23 43 0.02; Chi² = Z = 1.64 (P Events 138 16 326 51 91 176 29 19	Total 35 112 311 303 51 112 924 = 12.13, 4 = 0.10) iation Total 239 35 621 112 219 305 51 31	Events 13 42 153 218 32 60 518 df = 5 (P = Late initi Events 128 13 269 43 102 224 38 49	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36 592 112 220 304 47 89	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% ² = 59% ² = 59% 12.8% 4.7% 13.8% 9.1% 11.5% 13.7% 13.5% 13.5%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89] 0.70 [0.53, 0.93] 1.11 [0.79, 1.56]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016 Shiao 2009	Events 16 48 150 170 23 43 0.02; Chi² = Z = 1.64 (P Events 138 16 326 51 91 176 29	Total 35 112 311 303 51 112 924 = 12.13, + = 0.10) iation Total 239 35 621 112 219 303 51 51 52 52 52 52 52 52 52 52 52 52	Events 13 42 153 218 32 60 518 df = 5 (P = Late initit Events 128 13 269 43 224 38	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36 592 112 220 304 47	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% 2 = 59% Weight 12.8% 4.7% 13.8% 9.1% 13.7% 9.9%	M-H, Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] M-H, Random, 95% C 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89] 0.70 [0.53, 0.93]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: <u>Study or Subgroup</u> Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016 Shiao 2009 Shum 2012	Events 16 48 150 170 23 43 0.02; Chi² = Z = 1.64 (P Events 138 16 326 51 91 176 29 19	Total 35 112 311 303 51 112 924 = 12.13, 4 = 0.10) iation Total 239 35 621 112 219 305 51 31	Events 13 42 153 218 32 60 518 df = 5 (P = Late initi Events 128 13 269 43 102 224 38 49	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36 592 112 220 304 47 89	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% ² = 59% ² = 59% 12.8% 4.7% 13.8% 9.1% 11.5% 13.7% 13.5% 13.5%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89] 0.70 [0.53, 0.93] 1.11 [0.79, 1.56]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016 Shiao 2009 Shum 2012 Zarkbock 2016	Events 16 48 150 23 43 450 0.02; Chi ² = Z = 1.64 (P Early initi Events 138 16 326 51 91 176 29 19 10	Total 35 112 311 303 51 112 924 = 12.13, (= 0.10) iation Total 239 355 621 112 219 303 51 311 311 20	Events 13 42 153 218 32 60 518 df = 5 (P = Late initit Events 128 3269 43 102 224 38 49 45	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36 592 112 220 304 47 89 53 119	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% ² = 59% ² = 59% ³ = 59% 12.8% 4.7% 9.1% 11.5% 13.8% 9.1% 13.5% 6.3%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] M-H. Random. 95% C 1.07 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89] 0.70 [0.53, 0.93] 1.11 [0.79, 1.56] 0.59 [0.37, 0.93]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016 Shiao 2009 Shum 2012 Wu 2012 Zarkbock 2016 Total (95% CI)	Events 16 48 150 170 23 43 0.02; Chi² = $Z = 1.64$ (P Early initi Events 138 16 326 51 91 176 29 19 10 44	Total 35 112 311 303 51 112 924 = 12.13, - = 0.10) iation Total 239 35 621 112 239 35 621 112 219 303 51 31 20 112	Events 13 42 153 218 32 60 518 df = 5 (P = Late initit Events 128 13 269 43 102 224 38 49 45 65	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 36 592 112 220 304 47 89 53 119	6.4% 14.0% 24.5% 27.4% 12.2% 100.0% 2 = 59% 2 = 59% 2 = 59% 2 = 59% 2 = 59% 12.8% 4.7% 13.8% 9.1% 11.5% 13.7% 9.9% 8.5% 6.3% 9.7%	M-H, Random, 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.88] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89] 0.70 [0.53, 0.93] 1.11 [0.79, 1.56] 0.59 [0.37, 0.93] 0.72 [0.54, 0.95]	M-H. Rand	tom, 95% Cl
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016 Shiao 2009 Shum 2012 Wu 2012 Zarkbock 2016 Total (95% CI) Total events	Events 16 48 150 170 23 43 0.02; Chi ² = Z = 1.64 (P Early initi Events 138 16 326 51 91 176 29 19 10 44 900	Total 35 112 311 303 51 112 924 = 12.13, i = 0.10) iation Total 239 3621 112 219 303 51 31 20 112 1743	Events 13 42 153 218 32 60 518 df = 5 (P = Late initit Events 128 13 269 43 102 224 38 49 45 65 976	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 364 592 112 2200 304 477 89 53 119 1810	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% ² = 59% ² = 59% ³ - 59% 12.8% 4.7% 13.8% 9.1% 11.5% 13.8% 9.1% 13.5% 6.3% 9.7% 100.0%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.83] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89] 0.70 [0.53, 0.93] 1.11 [0.79, 1.56] 0.59 [0.37, 0.93] 0.72 [0.54, 0.95] 0.92 [0.79, 1.07]	I M-H. Rand	tom, 95% CI
Bouman 2002 Combes 2015 Gaudry 2018 Park 2016 Shiao 2009 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Christiansen 2017 Combes 2015 Jun 2014 Park 2016 Shiao 2009 Shum 2012 Wu 2012 Zarkbock 2016 Total (95% CI)	Events 16 48 150 23 43 450 0.02; Chi ² = Z = 1.64 (P Early initi Events 138 16 326 51 91 176 29 19 10 44 900 0.04; Chi ² =	Total 35 112 311 303 51 112 924 = 12.13, (= 0.10) iation Total 239 355 621 112 219 303 51 311 20 112 1743 : 40.08, c	Events 13 42 153 218 32 60 518 df = 5 (P = Late initit Events 128 13 269 43 102 224 38 49 45 65 976	Total 36 112 308 304 47 119 926 0.03); F ation Total 238 364 592 112 2200 304 477 89 53 119 1810	6.4% 14.0% 24.5% 27.4% 12.2% 15.4% 100.0% ² = 59% ² = 59% ² = 59% ³ - 59% 12.8% 4.7% 13.8% 9.1% 11.5% 13.8% 9.1% 13.5% 6.3% 9.7% 100.0%	M-H. Random. 95% C 1.27 [0.72, 2.23] 1.14 [0.83, 1.58] 0.97 [0.83, 1.14] 0.78 [0.69, 0.83] 0.66 [0.46, 0.95] 0.76 [0.57, 1.02] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 0.88 [0.75, 1.03] 1.07 [0.91, 1.26] 1.27 [0.72, 2.23] 1.16 [1.03, 1.30] 1.19 [0.87, 1.62] 0.90 [0.73, 1.11] 0.79 [0.70, 0.89] 0.70 [0.53, 0.93] 1.11 [0.79, 1.56] 0.59 [0.37, 0.93] 0.72 [0.54, 0.95] 0.92 [0.79, 1.07]	M-H. Rand	tom, 95% CI
	Combes 2015 Demirkilic 2004 Elahi 2004 Gettings 1999 Iyem 2009 Park 2016 Shiao 2009 Shum 2012 Sugahara 2004 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Barbar 2018 Bouman 2002 Combes 2015 Jun 2014 Oh 2016 Park 2016 Shiao 2009 Shum 2012 Tian 2014 Wu 2012 Zarkbock 2016 Total (95% CI) Total events Heterogeneity: Chi ² =	Combes 2015 50 Demirkilic 2004 6 Elahi 2004 8 Gettings 1999 25 Iyem 2009 5 Park 2016 121 Shiao 2009 22 Shum 2012 17 Sugahara 2004 2 Total (95% CI) 7 Total events 283 Heterogeneity: Tau ² = 0.06; Chi ² = Test for overall effect: Z = 2.24 (P Early init Study or Subgroup Events Barbar 2018 111 Bouman 2002 11 Combes 2015 40 Jun 2014 82 Oh 2016 9 Park 2016 163 Shian 2009 14 Shum 2012 15 Tian 2014 6 Wu 2012 8 Zarkbock 2016 34 Total events 560 Heterogeneity: Chi ² = 22.69, df =	Combes 2015 50 112 Demirkilic 2004 6 27 Elahi 2004 8 28 Gettings 1999 25 41 lyem 2009 5 95 Park 2016 121 303 Shiao 2009 22 51 Shum 2012 17 31 Sugahara 2004 2 14 Total (95% CI) 752 Total events 283 Heterogeneity: Tau ² = 0.06; Chi ² = 26.31, c Total events 283 Heterogeneity: Tau ² = 0.06; Chi ² = 26.31, c Total 2 Total events 283 Heterogeneity: Tau ² = 0.06; Chi ² = 26.31, c 15 Test for overall effect: Z = 2.24 (P = 0.03) Early initiation Study or Subgroup Events Total Barbar 2018 111 239 239 2014 31 Stiao 2015 40 112 30 112 30 Dh 2016 9 30 303 313 313 314 51 311	Combes 2015 50 112 44 Demirkilic 2004 6 27 19 Elahi 2004 8 28 12 Gettings 1999 25 41 47 Iyem 2009 5 95 6 Park 2016 121 303 182 Shiao 2009 22 51 35 Shum 2012 17 31 48 Sugahara 2004 2 14 12 Total (95% CI) 752 Total events 283 429 Heterogeneity: Tau ² = 0.06; Chi ² = 26.31, df = 10 (P = Total Events 102 Bourbar 2018 111 239 102 102 Bourbar 2018 111 239 102 102 Bourbar 2015 40 112 40 Jun 2014 82 219 84 Oh 2012 67 105 92 Oh 2012 67 103 204 Shiao 2009 14 <td< td=""><td>Combes 2015 50 112 44 112 Demirkilic 2004 6 27 19 34 Elahi 2004 8 28 12 36 Gettings 1999 25 41 47 59 yem 2009 5 95 6 90 Park 2016 121 303 182 304 Shiao 2009 22 51 35 47 Shum 2012 17 31 48 89 Sugahara 2004 2 14 12 14 Total (95% CI) 752 836 70 Total events 283 429 429 Heterogeneity: Tau² = 0.06; Chi² = 26.31, df = 10 (P = 0.003) Total 70 Test for overall effect: Z = 2.24 (P = 0.03) Events Total 80 Barbar 2018 111 239 102 238 Bouman 2002 111 35 9 36 Cohbes 2015 40 112 40 11</td><td>Combes 2015 50 112 44 112 13.1% Demirkilic 2004 6 27 19 34 5.4% Elahi 2004 8 28 12 36 5.6% Gettings 1999 25 41 47 59 13.9% Park 2016 121 303 182 304 16.4% Shiao 2009 22 51 35 47 12.0% Shum 2012 17 31 48 89 11.6% Sugahara 2004 2 14 12 14 2.3% Total (95% CI) 752 836 100.0% Total events 283 429 429 Heterogeneity: Tau² = 0.06; Chi² = 26.31, df = 10 (P = 0.003); l² = 62% 76 Total vor Subgroup Events Total Events Total Barbar 2018 111 239 102 238 15.1% Bouman 2002 11 35 9 36 1.3%</td><td>Combes 2015 50 112 44 112 13.1% 1.14 $[0.83, 1.55]$ Demirkilic 2004 6 27 19 34 5.4% 0.40 $[0.18, 0.86]$ Elahi 2004 8 28 12 36 5.6% 0.86 $[0.41, 1.81]$ Gettings 1999 25 41 47 59 13.9% 0.77 $[0.58, 1.01]$ Iyem 2009 5 95 6 90 2.8% 0.79 $[0.52, 2.50]$ Park 2016 121 303 182 304 16.4% 0.67 $[0.57, 0.79]$ Shiao 2009 22 51 35 47 12.0% 0.58 $[0.41, 0.83]$ Sugahara 2004 2 14 12 14 2.3% 0.17 $[0.05, 0.61]$ Total events 283 429 429 429 429 429 420 12.4% $[0.80, 1.32]$ 10.2 $[0.64, 0.97]$ 70.4 48 12 19.3% 1.26 $[0.59, 2.66]$ Combes 2015 40 112 40 112 5.9%</td><td>Combes 2015 50 112 44 112 13.1% 1.14 0.83, 1.55 Demirklic 2004 6 27 19 34 5.4% 0.40 0.18, 0.86 Elahi 2004 8 28 12 36 5.6% 0.86 [0.41, 1.81] Gettings 1999 25 41 47 59 13.9% 0.77 [0.58, 1.01] Iver 2009 5 95 6 90 2.8% 0.79 [0.25, 2.50] Park 2016 121 303 182 304 16.4% 0.67 [0.57, 0.79] • Shiao 2009 22 51 35 47 12.0% 0.58 [0.41, 0.83] • Sugahara 2004 2 14 12 14 2.3% 0.17 [0.05, 0.61] • Total (95% Cl) 752 836 100.0% 0.79 [0.64, 0.97] • Total events 283 429 • • • • • • • • • • • • • •</td></td<>	Combes 2015 50 112 44 112 Demirkilic 2004 6 27 19 34 Elahi 2004 8 28 12 36 Gettings 1999 25 41 47 59 yem 2009 5 95 6 90 Park 2016 121 303 182 304 Shiao 2009 22 51 35 47 Shum 2012 17 31 48 89 Sugahara 2004 2 14 12 14 Total (95% CI) 752 836 70 Total events 283 429 429 Heterogeneity: Tau ² = 0.06; Chi ² = 26.31, df = 10 (P = 0.003) Total 70 Test for overall effect: Z = 2.24 (P = 0.03) Events Total 80 Barbar 2018 111 239 102 238 Bouman 2002 111 35 9 36 Cohbes 2015 40 112 40 11	Combes 2015 50 112 44 112 13.1% Demirkilic 2004 6 27 19 34 5.4% Elahi 2004 8 28 12 36 5.6% Gettings 1999 25 41 47 59 13.9% Park 2016 121 303 182 304 16.4% Shiao 2009 22 51 35 47 12.0% Shum 2012 17 31 48 89 11.6% Sugahara 2004 2 14 12 14 2.3% Total (95% CI) 752 836 100.0% Total events 283 429 429 Heterogeneity: Tau ² = 0.06; Chi ² = 26.31, df = 10 (P = 0.003); l ² = 62% 76 Total vor Subgroup Events Total Events Total Barbar 2018 111 239 102 238 15.1% Bouman 2002 11 35 9 36 1.3%	Combes 2015 50 112 44 112 13.1% 1.14 $[0.83, 1.55]$ Demirkilic 2004 6 27 19 34 5.4% 0.40 $[0.18, 0.86]$ Elahi 2004 8 28 12 36 5.6% 0.86 $[0.41, 1.81]$ Gettings 1999 25 41 47 59 13.9% 0.77 $[0.58, 1.01]$ Iyem 2009 5 95 6 90 2.8% 0.79 $[0.52, 2.50]$ Park 2016 121 303 182 304 16.4% 0.67 $[0.57, 0.79]$ Shiao 2009 22 51 35 47 12.0% 0.58 $[0.41, 0.83]$ Sugahara 2004 2 14 12 14 2.3% 0.17 $[0.05, 0.61]$ Total events 283 429 429 429 429 429 420 12.4% $[0.80, 1.32]$ 10.2 $[0.64, 0.97]$ 70.4 48 12 19.3% 1.26 $[0.59, 2.66]$ Combes 2015 40 112 40 112 5.9%	Combes 2015 50 112 44 112 13.1% 1.14 0.83, 1.55 Demirklic 2004 6 27 19 34 5.4% 0.40 0.18, 0.86 Elahi 2004 8 28 12 36 5.6% 0.86 [0.41, 1.81] Gettings 1999 25 41 47 59 13.9% 0.77 [0.58, 1.01] Iver 2009 5 95 6 90 2.8% 0.79 [0.25, 2.50] Park 2016 121 303 182 304 16.4% 0.67 [0.57, 0.79] • Shiao 2009 22 51 35 47 12.0% 0.58 [0.41, 0.83] • Sugahara 2004 2 14 12 14 2.3% 0.17 [0.05, 0.61] • Total (95% Cl) 752 836 100.0% 0.79 [0.64, 0.97] • Total events 283 429 • • • • • • • • • • • • • •

	Early init	ation	Late imit	ation		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Christiansen 2017	125	141	129	162	19.6%	1.11 [1.01, 1.23]	•
Combes 2015	60	112	66	112	15.5%	0.91 [0.72, 1.15]	+
Gettings 1999	16	16	11	12	16.1%	1.10 [0.89, 1.36]	+
Shiao 2009	22	51	10	47	5.8%	2.03 [1.08, 3.82]	
Shum 2012	15	16	44	46	18.5%	0.98 [0.85, 1.13]	+
Tian 2014	18	23	26	77	10.8%	2.32 [1.59, 3.39]	
Zarkbock 2016	60	112	46	119	13.7%	1.39 [1.04, 1.84]	-
Total (95% CI)		471		575	100.0%	1.21 [1.01, 1.45]	◆
Total events	316		332				
Heterogeneity: Tau ² =	0.04; Chi² :	= 29.56,	df = 6 (P <	0.0001); I ² = 80%		
Test for overall effect:	Z = 2.11 (P	= 0.03)					0.01 0.1 1 10 100 Early initation Late imitation
GURE 6 Forest plot for re	nal recoverv	after co	ntinuous rer	al replac	ement ther	any (CBBT)	

situations; thus, we cannot take these studies into our metaanalysis, as they might influence our conclusion. We believed that these disagreements mainly come from the definition of early and late that the authors adopted, as in essence was based on the time period. This can also support our view that the timing definition based on the disease severity should be accounted first when discussing CRRT initiation. Other reasons for this disagreement might be the dialysis method chosen in the study of Barbar et al. (38) and no RRT method nor composition of different RRT was described; CRRT as a more positive dialysis method can remove the metabolic wastes continuously and gradually correct the fluid overload. In fact, when the disease was in an early stage, regular hemodialysis rather than CRRT is more likely employed, and this difference in RRT method composition in early and late groups can be the source of the divergence between our study and those of Barbar et al. (38) and Gaudry et al. (39). Theoretically, with appropriate intervention time, CRRT will be more appropriate in maintaining the hemodynamic stability and homeostasis in the patients with AKI and significantly improve the prognosis of the patient and reduce mortality.

Similarly, Gaudry et al. (39) had conducted an meta-analysis and found no benefits of early and late initiation of RRT on 28day (RR 1.01, 95% CI 0.91–1.13) or 90-day (RR 0.38, 95% CI 0.83–1.16) mortality in 2020, we think this disagreement might also come out from the definition of early and late in the studies they enroll. Most of the early strategy is defined as an RRT conduct at any or late stage of Kidney International Improving Global Outcomes (KIDIGO), RIFLE, and AKIN without serious complications, which is partly contained in our late group. In fact, we believe their negative conclusion is not a symbol saying the timing of RRT initiation is not really important, otherwise, it should remind us to pay further attention to the studies of AKI severity degree of CRRT initiation timing.

This study found benefits of earlier CRRT, especially when its timing was defined by the disease severity, in other words, CRRT was initiated based on an earlier disease stage. In this study, CCRT initiated in patients with AKIN stage 1 or RIFLE-Risk or less stage might lead to a better prognosis for the patients with AKI admitted in ICU. The possible mechanisms might benefit from the lower overall cumulative fluid balance, gentler osmolar shifts, and effective and timely clearance of inflammatory factors and other body wastes, which can prevent the hemodynamic imbalance and further kidney damage in theory (40). Our discussion cannot provide a specific answer, as the mechanisms and pathways still remained to be elucidated.

The heterogeneities across the studies were found in our analyses. Considering that the heterogeneity can arise from different definitions of early and late timing, we conducted the subgroup analysis to assess the effects in the subgroups of timebased studies, disease severity-based studies, studies re-grouped based on time, and studies re-grouped based on the disease severity to measure the effect of early vs. late initiation of CRRT on in-hospital and 28- or 30-day mortalities. However, 60-day mortality, 90-day mortality, and renal recovery after dialysis were beyond this subgroup analysis because not enough trials had provided this information. After the subgroup analysis, the heterogeneity between each trial was known (<75%). Similar results were found in the disease severity-based studies and the studies re-grouped based on the disease severity, while in the subgroups of studies based on time of CRRT initiation and the studies re-grouped based on time, the benefit of early CRRT was not so significant. This may be because the patients requiring early CRRT, as defined by time in observational studies, usually had greater risk and more severe disease and the number of relevant studies was limited.

This study has several limitations. Firstly, only five RCTs were included, the rest were all non-RCTs, and the quality of these studies was limited. Secondly, the publication bias existed because only a small number of studies met our inclusion criteria, which may lead to an overstated beneficial effect of early CRRT on mortality and renal recovery after therapy compared with late CRRT. Thirdly, no meta-regression analysis was conducted to assess the heterogeneity factors. Finally, only mortalities and renal recovery conditions were measured in this study; secondary outcomes, such as length of hospital or ICU stay, vasopressor requirement, bleeding events, and mechanical ventilation were not measured because of the lack of available data.

	Early init Events		Late initi Events		Woight	Risk Ratio M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl
<u>Study or Subgroup</u> ime based	Events	Total	Events	Total	weight	M-H, Kandom, 95% CI	M-H, Random, 95% Cl
Cardenas 2015	9	15	10	15	4.7%	0 00 [0 52 1 55]	
/em 2009	9 5	95	6	90	4.7%	0.90 [0.52, 1.55] 0.79 [0.25, 2.50]	
Subtotal (95% CI)	5	110	0	105	6.1%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44]	•
otal events	14	110	16	105	0.170	0.00 [0.04, 1.44]	
leterogeneity: Tau ² = (0.05 df		1 821.12 -	- 0%		
est for overall effect: 2	,	,	- 1 (1 - 0	<i>2)</i> , r -	- 0 /0		
Disease severity base	ed						
Combes 2015	50	112	44	112	9.3%	1.14 [0.83, 1.55]	+-
emirkilic 2004	6	27	19	34	2.8%	0.40 [0.18, 0.86]	
lahi 2004	8	28	12	36	2.9%	0.86 [0.41, 1.81]	
Settings 1999	25	41	47	59	10.2%	0.77 [0.58, 1.01]	-
Park 2016	121	303	182	304	13.7%	0.67 [0.57, 0.79]	-
Shiao 2009	22	51	35	47	8.0%	0.58 [0.41, 0.83]	
Shum 2012	17	31	48	89	7.7%	1.02 [0.70, 1.48]	+
Sugahara 2004	2	14	12	14	1.1%	0.17 [0.05, 0.61]	
ubtotal (95% CI)		607		695	55.6%	0.73 [0.58, 0.93]	•
otal events	251		399				
leterogeneity: Tau² = (est for overall effect: 2			ר (P = 1 (P =	0.003);	1 07 %		
•							
Re-grouped based o n Cardenas 2015	9	15	10	15	4.7%	0.90 [0.52, 1.55]	-
Cardenas 2015 yem 2009		15 95	10 6	90	1.4%	0.79 [0.25, 2.50]	
Cardenas 2015 yem 2009 Subtotal (95% CI)	9 5	15	6				•
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events	9 5 14	15 95 110	6 16	90 105	1.4% 6.1%	0.79 [0.25, 2.50]	•
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = 0	9 5 14 0.00; Chi² =	15 95 110 0.05, df	6 16	90 105	1.4% 6.1%	0.79 [0.25, 2.50]	•
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events leterogeneity: Tau ² = (Test for overall effect: 2	9 5 14 0.00; Chi² = Z = 0.51 (P	15 95 110 0.05, df = 0.61)	6 16	90 105	1.4% 6.1%	0.79 [0.25, 2.50]	•
Cardenas 2015 yem 2009 Gubtotal (95% CI) Total events leterogeneity: Tau ² = (Test for overall effect: 2 Re-grouped based or	9 5 14 0.00; Chi² = Z = 0.51 (P	15 95 110 0.05, df = 0.61)	6 16	90 105	1.4% 6.1%	0.79 [0.25, 2.50]	
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Re-grouped based or Demirkilic 2004	9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s	15 95 110 0.05, df = 0.61) everity	6 16 = 1 (P = 0	90 105).82); I² =	1.4% 6.1% = 0%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44]	
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Re-grouped based or Demirkilic 2004	9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6	15 95 110 0.05, df = 0.61) everity 27	6 16 = 1 (P = 0 19	90 105).82); I ² = 34	1.4% 6.1% = 0%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.40 [0.18, 0.86]	•
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Re-grouped based or Demirkilic 2004 Elahi 2004 Park 2016	9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6 8	15 95 110 0.05, df = 0.61) everity 27 28	6 16 7 = 1 (P = 0 19 12	90 105).82); I ² = 34 36	1.4% 6.1% = 0% 0.0% 2.9%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.40 [0.18, 0.86] 0.86 [0.41, 1.81]	
Cardenas 2015 vem 2009 Subtotal (95% CI) Sotal events Seterogeneity: Tau ² = (Set for overall effect: 2 Re-grouped based or Demirkilic 2004 Stahi 2004 Stahi 2004 Stahi 2004 Stahi 2009 Shum 2012	9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6 8 121	15 95 110 0.05, df = 0.61) everity 27 28 303 51 31	6 16 = 1 (P = 0 19 12 182	90 105).82); ² = 34 36 304 47 89	1.4% 6.1% = 0% 0.0% 2.9% 13.7% 8.0% 7.7%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.40 [0.18, 0.86] 0.86 [0.41, 1.81] 0.67 [0.57, 0.79] 0.58 [0.41, 0.83] 1.02 [0.70, 1.48]	
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Re-grouped based or Demirkilic 2004 Stahi 2004 Park 2016 Shiao 2009 Shum 2012	9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6 8 121 22	15 95 110 0.05, df = 0.61) everity 27 28 303 51	6 16 = 1 (P = 0 19 12 182 35	90 105).82); ² = 34 36 304 47	1.4% 6.1% = 0% 0.0% 2.9% 13.7% 8.0%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.40 [0.18, 0.86] 0.86 [0.41, 1.81] 0.67 [0.57, 0.79] 0.58 [0.41, 0.83]	
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Re-grouped based or Demirkilic 2004 Elahi 2004 Park 2016 Shiao 2009 Shum 2012 Subtotal (95% CI)	9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6 8 121 22	15 95 110 0.05, df = 0.61) everity 27 28 303 51 31	6 16 = 1 (P = 0 19 12 182 35	90 105).82); ² = 34 36 304 47 89	1.4% 6.1% = 0% 0.0% 2.9% 13.7% 8.0% 7.7%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.40 [0.18, 0.86] 0.86 [0.41, 1.81] 0.67 [0.57, 0.79] 0.58 [0.41, 0.83] 1.02 [0.70, 1.48]	
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Re-grouped based or Demirkilic 2004 Eahi 2004 Park 2016 Shiao 2009 Shum 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6 8 121 22 17 168 0.03; Chi ² =	15 95 110 0.05, df = 0.61) everity 27 28 303 51 31 413 5.54, df	6 16 19 12 182 35 48 277 1 = 3 (P = 0	90 105).82); ² = 34 36 304 47 89 476	1.4% 6.1% = 0% 0.0% 2.9% 13.7% 8.0% 7.7% 32.3%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.40 [0.18, 0.86] 0.86 [0.41, 1.81] 0.67 [0.57, 0.79] 0.58 [0.41, 0.83] 1.02 [0.70, 1.48]	
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events deterogeneity: Tau ² = (cest for overall effect: 2 Re-grouped based or Demirkilic 2004 Carls 2004 Park 2016 Shiao 2009 Shum 2012 Subtotal (95% CI) Total events deterogeneity: Tau ² = (cest for overall effect: 2 Total (95% CI)	9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6 8 121 22 17 168 0.03; Chi ² = Z = 2.68 (P	15 95 110 0.05, df = 0.61) everity 27 28 303 51 31 413 5.54, df	6 16 19 12 182 35 48 277 5 = 3 (P = 0	90 105).82); ² = 34 36 304 47 89 476).14); ² =	1.4% 6.1% = 0% 0.0% 2.9% 13.7% 8.0% 7.7% 32.3%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.40 [0.18, 0.86] 0.86 [0.41, 1.81] 0.67 [0.57, 0.79] 0.58 [0.41, 0.83] 1.02 [0.70, 1.48]	
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events deterogeneity: Tau ² = (Test for overall effect: 2 Re-grouped based or Demirkilic 2004 Stahi 2004 Park 2016 Shiao 2009 Shum 2012 Subtotal (95% CI) Total events deterogeneity: Tau ² = (Total (95% CI) Total events Total events State of the state of the sta	9 5 14 0.00; Chi ² = Z = 0.51 (P) n disease s 6 8 121 22 17 168 0.03; Chi ² = Z = 2.68 (P) 447	15 95 110 0.05, df = 0.61) everity 27 28 303 51 31 413 5.54, df = 0.007) 1240	6 16 19 12 182 35 48 277 5 = 3 (P = 0 708	90 105).82); ² = 34 36 304 47 89 476).14); ² = 1381	1.4% 6.1% = 0% 0.0% 2.9% 13.7% 8.0% 7.7% 32.3% = 46% 100.0%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.86 [0.41, 1.81] 0.67 [0.57, 0.79] 0.58 [0.41, 0.83] 1.02 [0.70, 1.48] 0.73 [0.57, 0.92]	
Cardenas 2015 yem 2009 Subtotal (95% CI) Total events leterogeneity: Tau ² = (cest for overall effect: 2 Re-grouped based or Demirkilic 2004 Schar 2004 Park 2016 Shiao 2009 Shum 2012 Subtotal (95% CI) Total events leterogeneity: Tau ² = (Cotal (95% CI) Total events leterogeneity: Tau ² = (9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6 8 121 22 17 168 0.03; Chi ² = Z = 2.68 (P 447 0.03; Chi ² =	15 95 110 0.05, df = 0.61) everity 27 28 303 51 31 413 5.54, df = 0.007) 1240 28.53, c	$ \begin{array}{c} $	90 105).82); ² = 34 36 304 47 89 476).14); ² = 1381	1.4% 6.1% = 0% 0.0% 2.9% 13.7% 8.0% 7.7% 32.3% = 46% 100.0%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.86 [0.41, 1.81] 0.67 [0.57, 0.79] 0.58 [0.41, 0.83] 1.02 [0.70, 1.48] 0.73 [0.57, 0.92]	
•	9 5 14 0.00; Chi ² = Z = 0.51 (P n disease s 6 8 121 22 17 168 0.03; Chi ² = Z = 2.68 (P 447 0.03; Chi ² = Z = 3.95 (P	15 95 110 0.05, df = 0.61) everity 27 28 303 51 31 413 5.54, df = 0.007) 1240 28.53, c < 0.000	$ \begin{array}{c} 6 \\ 16 \\ $	90 105).82); ² = 34 36 304 47 89 476).14); ² = 1381 = 0.02);	1.4% 6.1% = 0% 0.0% 2.9% 13.7% 8.0% 7.7% 32.3% = 46% 100.0% ² = 47%	0.79 [0.25, 2.50] 0.88 [0.54, 1.44] 0.86 [0.41, 1.81] 0.67 [0.57, 0.79] 0.58 [0.41, 0.83] 1.02 [0.70, 1.48] 0.73 [0.57, 0.92]	0.01 0.1 1 10 10 Early initiation Late initiation

Although several previous systematic reviews and metaanalyses focused on the RRT timing of the patients with AKI (11, 12, 40, 41), none of these studies focused on CRRT, nor did the trials investigated early and late CRRT separately. This can be a source of heterogeneity. As each of these factors was evaluated in our study, we found that the definition of the initiation timing based on the disease severity may be more effective and beneficial.

Further prospective interventional, large, multicenter trails are necessary to discover the degree of disease severity on the timing of CRRT initiation and to provide more powerful evidence. Further studies should focus on the long-term prognosis to find the relationship between the CRRT initiation timing and chronic kidney disease after AKI.

CONCLUSION

Compared with late CRRT, early CRRT can provide a favorable influence on the short-term mortality (e.g., in-hospital mortality and 28- or 30-day mortality) and renal recovery after CRRT, but the effects of different timing of CRRT initiation on longterm mortality remain unclear. Defining initiation timing by disease severity might be more effective. CRRT initiation on the

Study or Subgroup	Events						
	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Time based							
Jun 2014	82	219	84	220	8.6%	0.98 [0.77, 1.25]	+
Oh 2012	67	105	92	105	13.7%	0.73 [0.62, 0.86]	*
Oh 2016	9	30	17	30	1.7%	0.53 [0.28, 0.99]	
Subtotal (95% CI)		354		355	24.1%	0.78 [0.59, 1.04]	\bullet
Total events	158		193				
Heterogeneity: Tau ² = 0	0.04; Chi ² =	6.09, df	= 2 (P = 0).05); l ² =	= 67%		
Test for overall effect: 2	Z = 1.72 (P	= 0.09)					
Disease severity base	ed						
Combes 2015	40	112	40	112	4.9%	1.00 [0.70, 1.42]	+
Park 2016	163	303	204	304	16.4%	0.80 [0.70, 0.91]	-
Shiao 2009	14	51	19	47	2.1%	0.68 [0.39, 1.20]	+
Shum 2012	16	31	46	89	4.0%	1.00 [0.67, 1.48]	+
Tian 2014	6	23	43	77	1.4%	0.47 [0.23, 0.96]	<u> </u>
Wu 2012	8	20	41	53	2.2%	0.52 [0.30, 0.90]	
Subtotal (95% CI)	0	540		682	31.0%	0.79 [0.65, 0.96]	•
Total events	247	5.0	393	501		5	
Heterogeneity: $Tau^2 = 0$		7 66 4) 18)· l² -	= 35%		
Test for overall effect: 2		10 CONTRACT. CAR.	- 5 (1 - 0	<i></i>	- 5570		
Re-grouped based or							
Jun 2014	82	219	84	220	8.6%	0.98 [0.77, 1.25]	
Oh 2012	67	105	92	105	13.7%	0.73 [0.62, 0.86]	
Subtotal (95% CI)		324		325	22.4%	0.84 [0.61, 1.15]	
Total events	149		176				
Heterogeneity: Tau ² = 0			[•] = 1 (P = 0).03); l² =	= 79%		
Test for overall effect: 2	Z = 1.11 (P	= 0.27)					
Re-grouped based of	n disease s	severity					
Park 2016	163	303	204	304	16.4%	0.80 [0.70, 0.91]	=
Shiao 2009	14	51	19	47	2.1%	0.68 [0.39, 1.20]	+
Shum 2012	16	31	46	89	4.0%	1.00 [0.67, 1.48]	,+
Subtotal (95% CI)		385		440	22.6%	0.81 [0.72, 0.92]	♦
Total events	193		269				
Heterogeneity: Tau ² = 0		1.47. df).48): l² =	= 0%		
Test for overall effect: 2				- // -			
Total (95% CI)		1603		1802	100.0%	0.81 [0.74, 0.88]	•
Total events	747		1031			0.01 [0.1.1, 0.00]	
Heterogeneity: $Tau^2 = 0$		19 21 /		= 0 12)	$ ^2 = 32\%$		· · · · · ·
Test for overall effect: 2				0.12),	- 52 /0		0.01 0.1 1 10 100
Test for subaroup diffe			,	- 0.08)	12 - 0%		Early initiation Late initiation
I ESLIDI SUDUTOUD dIME	rences: Chi	- 0.15.	ui – 5 (P :	- 0.901.	- 0%		

patients with AKIN stage 1 or RIFLE-Risk or less may lead to a better prognosis. We suggest an early stage of AKI disease-CRRT initiation as a beneficial timing choice. Further prospective interventional, large, multicenter trails are warranted to establish the most appropriate initiation timing based on the disease severity and to determine the effectiveness of initiation timing related to the long-term prognosis.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

Z-JX, L-yH, and YL conceived the study and wrote the initial protocol and the manuscript. Z-JX and S-YP did the literature search. Z-JX, Q-PZ, and R-JC did the statistical analysis. All authors shared trial data, gave crucial feedback on the protocol, and provided critical revision for and approved the final version of the manuscript.

FUNDING

The present work was supported by the National Key Research and Development Program of China (Project No.

2016YFC0906201), the Key Research and Development Program of Sichuan Province (Project No. 2021YFS0166), and the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (Project No. ZYGD18015).

REFERENCES

- Bagshaw SM, George C, Bellomo R, ANZICS Database Management Committe. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. *Nephrol Dial Transplant*. (2008) 23:1569– 74. doi: 10.1093/ndt/gfn009
- Hoste EA, Kellum JA. Acute kidney injury: epidemiology and diagnostic criteria. *Curr Opin Crit Care.* (2006) 12:531– 7. doi: 10.1097/MCC.0b013e3280102af7
- Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Sock Nephrol. (2007) 18:1292–8. doi: 10.1681/ASN.2006070756
- Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA*. (2005) 294:813–8. doi: 10.1001/jama.294.7.813
- Paganini EP, Marshall MR. Acute renal replacement therapy in the intensive care unit. In: Feehally J, Floege J, Johnson R, editors. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier (2007).
- Baldwin I, Naka T, Koch B, Fealy N, Bellomo R. A pilot randomised controlled comparison of continuous veno-venoushaemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance. *Intensive Care Med.* (2007) 33:830–5. doi: 10.1007/s00134-007-0596-0
- De Vriese AS, Colardyn FA,Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous haemofiltration in septic patients. J Am Soc Nephrol. (1999) 10:846–53. doi: 10.1681/ASN.V104846
- Wald R, Bagshaw SM. The timing of renal replacement therapy initiation in acute kidney injury: is earlier truly better? *Crit Care Med.* (2014) 42:1933– 4. doi: 10.1097/CCM.00000000000432
- Conger J. Does hemodialysis delay recovery from acute renal failure? Semin Dial. (1990) 3:146–8. doi: 10.1111/j.1525-139X.1990.tb00031.x
- Shingarev R, Wille K, Tolwani A. Management of complications in renal replacement therapy. *Semin Dial.* (2011) 24:164– 8. doi: 10.1111/j.1525-139X.2011.00828.x
- Wang X, Yuan WJ, Timing of initiation of renal replacement therapy in acute kidney injury: asystematic review and meta-analysis. *Ren Fail*. (2012) 34:396–402. doi: 10.3109/0886022X.2011.647371
- Lai TS, Shiao CC, Wang JJ, Huang CT, Wu PC, Chueh E, et al. Earlier versus later initiation of renal replacement therapy among critically ill patients with acute kidney injury: a systematic review and metaanalysis of randomized controlled trials. *Ann Intensive Care.* (2017) 7:38. doi: 10.1186/s13613-017-0265-6
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Reprintpreferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PhysTher*. (2009) 89:873–80. doi: 10.1093/ptj/89.9.873
- 14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557
- Wells GA, Shea BJ, O'Connell D, Peterson J, Welch V, Losos M, et al. The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. *Appl Eng Agric.* (2014) 18:727–34. doi: 10.3346/jkms.2021.36.e98
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. *BMJ*. (1997) 315:629– 34. doi: 10.1136/bmj.315.7109.629
- Bouman CSC, Oudemans-Van Straaten HM, Tijssen JGP, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. *Crit Care Med.* (2002) 30:2205–11. doi: 10.1097/00003246-200210000-00005

ACKNOWLEDGMENTS

We thank all the researchers, patients, and surrogates involved in the individual trials. We thank Zi-yi Tang for assistance in data management.

- Sugahara S, Suzuki H. Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. *Hemodial Int.* (2004) 8:320–5. doi: 10.1111/j.1492-7535.2004.80404.x
- Jun M, Bellomo R, Cass A, Gallagher M, Lo S, Lee J, et al. Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study. *Crit Care Med.* (2014) 42:1756–65. doi: 10.1097/CCM.0000000000343
- Combes A, Bréchot N, Amour J, Cozic N, Lebreton G, Guidon C, et al. Early high-volume hemofiltration versus standard care for post-cardiac surgery shock. The HEROICS study. *Am J RespirCrit Care Med.* (2015) 192:1179– 90. doi: 10.1164/rccm.201503-0516OC
- Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. *JAMA*. (2016) 315:2190–9. doi: 10.1001/jama.2016.5828
- Demirkilic U, Kuralay E, Yenicesu M, Caglar K, Oz BS, Cingöz F, et al. Timing of replacement therapy for acute renal failure after cardiac surgery. J Card Surg. (2004) 19:17–20. doi: 10.1111/j.0886-0440.2004.04004.x
- 23. Oh HJ, Shin DH, Lee MJ, Koo HM, Doh FM, Kim HR, et al. Early initiation of continuous renal replacement therapy improves patient survival in severe progressive septic acute kidney injury. *J Crit Care.* (2012) 27:743.e9–18. doi: 10.1016/j.jcrc.2012.08.001
- Campos PC, Riera JS, Gonzalez GM, Velez VFC, Reveron JMV, Medina RSC, et al. Timing of continuous renal replacement therapies in acute kidney injury patients after cardiac surgery. *Intensive Care Med Exp.* (2015) 3:A261. doi: 10.1186/2197-425X-3-S1-A261
- Oh HJ, Kim MH, Ahn JY, Ku NS, Park JT, Han SH, et al. Can early initiation of continuous renal replacement therapy improve patient survival with septic acute kidney injury when enrolled in early goal-directed therapy? J Crit Care. (2016) 35:51–6. doi: 10.1016/j.jcrc.2016.04.032
- Park JY, An JN, Jhee JH, Kim DK, Oh HJ, Kim S, et al. Early initiation of continuous renal replacement therapy improves survival of elderly patients with acute kidney injury: a multicenter prospective cohort study. *Crit Care.* (2016) 20:260. doi: 10.1186/s13054-016-1437-8
- Gettings LG, Reynolds HN, Scalea T. Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late. *Intensive Care Med.* (1999) 25:805–13. doi: 10.1007/s001340050956
- Elahi MM, Lim MY, Joseph RN, Dhannapuneni RRV, Spyt TJ. Early hemofiltration improves survival in post-cardiotomy patients with acute renal failure. *Eur J Cardiothorac Surg.* (2004) 26:1027–31. doi: 10.1016/j.ejcts.2004.07.039
- Iyem H, Tavli M, Akcicek F, Büket S. Importance of early dialysis for acute renal failure after an open-heart surgery. *Hemodial Int.* (2009) 13:55– 61. doi: 10.1111/j.1542-4758.2009.00347.x
- 30. Shiao CC, Wu VC, Li WY, Lin YF, Hu FC, Young GH, et al. Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery. *Crit Care.* (2009) 13:R171. doi: 10.1186/cc8147
- Shum HP, Chan KC, Kwan MC, Yeung AW, Cheung EWS, et al. Timing for initiation of continuous renal replacement therapy in patients with septic shock and acute kidney injury. *TherApherDial.* (2013) 17:305– 310. doi: 10.1111/j.1744-9987.2012.01147.x
- 32. Wu SC, Fu CY, Lin HH, Chen RJ, Hsieh CH, Wang YC, et al. Late initiation of continuous veno-venous hemofiltration therapy is associated with a lower survival rate in surgical critically ill patients with postoperative acute kidney injury. *Am Surg.* (2012) 78:235–42. doi: 10.1177/000313481207800245
- 33. Tian H, Sun T, Hao D, Wang T, Li Z, Han S, et al. The optimal timing of continuous renal replacement therapy for patients

with sepsis-induced acute kidney injury. *IntUrolNephrol.* (2014) 46:2009-14. doi: 10.1007/s11255-014-0747-5

- 34. Christiansen S, Christensen S, Pedersen L,Gammelager H,Layton JB, Brookhart A, et al. Timing of renal replacement therapy and long-term risk of chronic kidney disease and death in intensive care patients with acute kidney injury. *Crit Care*. (2017) 21:326. doi: 10.1186/s13054-017-1903-y
- Ownby RL, Crocco E, Acevedo A, John V, Lowenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis. *Arch Gen Psychiatry*. (2006) 63:530–8. doi: 10.1001/archpsyc.63.5.530
- 36. Ricci Z, Ronco C, D'Amico G, De Felice R, Rossi S, Bolgan I, et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. *Nephrol Dial Transplant*. (2006) 21:690– 6. doi: 10.1093/ndt/gfi296
- Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. *N Engl J Med.* (2016) 375:122–33. doi: 10.1056/NEJMoa1603017
- Barbar SD, Clere-Jehl R, Bourredjem A, Hernu R, Montini F,Bruyère R, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N Engl J Me. (2018) 379:1431–42. doi: 10.1056/NEJMoa1803213
- 39. Gaudry S, Hajage D, Benichou N, Chaïbi K, Barbar S, Zarbock A, et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials. *Lancet.* (2020) 395:1506– 1515. doi: 10.1016/S0140-6736(20)350531-6
- 40. Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with

acute kidney injury: a meta-analysis. Crit Care Med. (2008) 36:610-7. doi: 10.1097/01.CCM.0B013E3181611F552

 Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. *Kidney Int.* (2001) 60:1154–63. doi: 10.1046/j.1523-1755.2001.060003 1154.x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Xia, He, Pan, Cheng, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.